Key Highlights

  • Amgen shares were trading up 3.63% at $478.02, against a prior close of $461.26.
  • Third-quarter Revenue of about $10.4 billion rose 8%, and adjusted EPS reached $6.45.
  • Prolia sales fell 45% and Xgeva sales fell 47% on biosimilar competition.
  • 2026 guidance was raised to adjusted EPS of $22.90 to $23.70.
  • UBS, Goldman Sachs, TD Cowen and Oppenheimer all raised price targets.

Price Target Hikes Outweigh a Muted After-Hours Reaction

Amgen (NASDAQ:AMGN) shares were trading up 3.63% at $478.02 on Wednesday, close to their 52-week high of $482.00. The move followed a third-quarter report that beat estimates and lifted the 2026 outlook. A broad health stock rally after Democratic midterm wins added support, with the Dow Jones Industrial Average up about 2.9%.

The initial after-hours reaction to the results was muted, but analysts moved quickly. UBS raised its target to $530, Goldman Sachs to $536, TD Cowen to $531 and Oppenheimer to $520.

Repatha, Evenity and Uplizna Offset Biosimilar Erosion

Adjusted EPS of $6.45 beat expectations on revenue of about $10.4 billion, up 8%. Six key growth drivers rose 27% and accounted for over 70% of product sales. Repatha sales reached about $1.1 billion, up 37%, Evenity $751 million, up 43%, Tezspire $538 million, up 43%, Uplizna $451 million, up 191%, and Imdelltra $406 million, more than double a year earlier.

Biosimilars are the drag. Prolia sales fell 45% and Xgeva sales fell 47%. Free Cash Flow was $3.7 billion, and the non-GAAP Operating Margin was 47%.

Three Positive Phase 3 Readouts and a MariTide Enrollment Milestone

Three Phase 3 trials read out positively in the quarter. Imdelltra plus Imfinzi in first-line maintenance small cell lung cancer showed median overall survival of 21.1 months against 12.7 months, Tezspire worked in eosinophilic esophagitis, and dazodalibep succeeded in Sjogren’s disease. A second dazodalibep Phase 3 in 434 patients is due in the fourth quarter, with detailed data at the ACR meeting on November 11.

Enrollment is complete for the MariTide Phase 3 sleep apnea and cardiovascular outcomes studies, with data expected next year.

Valuation Near 20 Times Forward Earnings After a Raised Outlook

2026 guidance now calls for adjusted EPS of $22.90 to $23.70 and a non-GAAP operating margin of about 45% to 46% of product sales, with Buybacks capped at $3 billion. The quarterly Dividend was $2.52 per share, up 6%, and the Yield is 2.08%.

The stock trades at 19.72 times forward earnings and 27.76 times trailing earnings, and consensus remains at Hold with an average target below the current price. The dazodalibep readout and ACR data are the next catalysts.